Zofran Information:

Zofran (Ondansetron), Zofran ODT (Ondansetron), and Zofran (Ondansetron) Oral Solution are indicated for prevention of postoperative nausea and vomiting (PONV), cancer chemotherapy-induced nausea and vomiting (CINV), and radiotherapy-induced nausea and vomiting (RINV). Zofran (Ondansetron), Zofran ODT (Ondansetron), and Zofran (Ondansetron) Oral Solution can be used for prevention of post-operative nausea and vommiting associated with highly emetogenic cancer chemotherapy,with initial and repeat courses of moderately emetogenic cancer chemotherapy. Only oral Zofran (Ondansetron) is indicated for days 2 and 3 following moderately emetogenic cancer chemotherapy.

Zofran (Ondansetron), Zofran ODT (Ondansetron), and Zofran (Ondansetron) Oral Solution can be used for prevention of post-operative nausea and vommiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen, in patients with high risk of PONV; as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively,Zofran (Ondansetron) Injection, Zofran (Ondansetron) Tablets, Zofran ODT (Ondansetron) (Orally Disintegrating Tablets), and Zofran (Ondansetron) Oral Solution are recommended even where the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic Zofran (Ondansetron) Injection and experience nausea and/or vomiting postoperatively, Zofran (Ondansetron) Injection may be given to prevent further episodes.

Zofran Side Effects:

Phenylketonurics: ZOFRAN ODT (Orally Disintegrating Tablets) contain phenylalanine. ZOFRAN is contraindicated for patients known to have hypersensitivity to the drug otherwise it may result in Zofran side effects. Zofran side effects like hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Each 4-mg and 8-mg Orally Disintegrating Tablet contains <0.03 mg phenylalanine (a component of aspartame).